HitGen Inc. A

Price Chart

Risk-Adjusted Performance

HitGen Inc. A (688222) Price Performance

HitGen Inc. A (688222) trades on SHG in CNY. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at CNY26.91, down 1.90% from the previous close.

Over the past year, 688222 has traded between a low of CNY13.99 and a high of CNY39.91. The stock has gained 92.4% over this period. It is currently 32.6% below its 52-week high.

HitGen Inc. A has a market capitalization of $10.69B, with a price-to-earnings ratio of 95.25.

About HitGen Inc. A

HitGen Inc. operates as a drug discovery research platform for small molecules and nucleic acid drugs in China and internationally. Its technology platform includes DNA-encoded library technology; fragment-based drug discovery and structure-based drug design technologies; emerging technology platforms for synthetic therapeutic oligonucleotide technology; and targeted protein degradation technology. The company's product pipeline also includes HG146, a selective HDAC inhibitor for multiple myeloma and solid tumor; HG030, a second generation NTRK/ROS1 inhibitor tablet for solid tumor; HG153 a Menin-MLL tablet; HG248; HG 381, an immune-oncology agonist for cancer, as well as HGP0508, a small molecule for anti-inflammatory therapeutics for inflammation; and HGP1069, a ROCK2 inhibitor eye drop. In addition, it offers target validation, hit identification, hit-to-lead optimization, lead optimization, preclinical studies and IND, clinical development, and integrated drug discovery services. Further, the company focuses on oncology and immuno-oncology, inflammatory and autoimmune diseases, ophthalmology, infectious, metabolic, and cardiovascular diseases. The company was incorporated in 2012 and is based in Chengdu, China.